WO2012103114A3 - Therapeutic chimeric ligand binding proteins and methods for their use - Google Patents

Abstract

Therapeutic chimeric ligand binding proteins are disclosed that are made from portions of at least two receptors that are fused into a single polypeptide sequence. The fused receptor portions can be derived from ErbB, an Axl receptor, FGFR, PDGFR, an Eph receptor, a Tie receptor, c-Kit receptor, a Trk receptor, a FLT3 receptor, the c-Met oncogene, or their family members and their isoforms. The resulting fusion protein has detectable binding activity for ligands that bind to each of its receptor substituents. DNA sequences that encode the chimeric ligand binding proteins are also contemplated along with sequences that facilitate expression and host cells for the maintenance and expression of such DNA sequences. Pharmaceutical compositions that contain the chimeric ligand binding proteins and a pharmaceutically acceptable excipient are also contemplated. Methods for treating patients having diseases that are associated with ligand binding are also contemplated that involve administering a pharmaceutical composition that contain therapeutically effective amounts of one or more of the chimeric ligand binding protein in a pharmaceutically acceptable excipient or using the chimeric ligand binding proteins to filter bodily fluids.